WASHINGTON, Feb 21 (Reuters) – AstraZeneca Plc said on Thursday it would appeal a jury ruling that it pay $215 million in damages, in an Alabama lawsuit related to drug pricing under the Medicaid health program for the needy.

A state jury ruled AstraZeneca should pay $40 million in compensatory damages and $175 million in punitive damages. The company was charged with reporting false pharmaceutical prices to Medicaid, the joint state-federal program that insures millions of individuals.

The case in the Circuit Court of Montgomery, Alabama, stemmed from a 2005 lawsuit filed by the Alabama Attorney General alleging AstraZeneca and dozens of other companies inflated prices to Medicaid.

The Anglo-Swedish drug company said it would appeal the case to the Alabama Supreme Court if a trial court did not reject the jury’s verdict that it said was based on “numerous errors” throughout the proceedings.

It will also file a motion that the punitive damages violate state law, which caps such damages at three times compensatory damages, according to AstraZeneca spokesman Tony Jewell.

Reporting by Kim Dixon; Editing by Braden Reddall, Richard Chang



We're here to help!

We live by our creed of “helping those who need it most” and have helped thousands of clients get the justice they desperately needed and deserved. If you feel you have a case or just have questions please contact us for a free consultation. There is no risk and no fees unless we win for you.

Fields marked * may be required for submission.


Respectful, understanding, efficient and compassionate

Beasley Allen is one of the most professional organizations I have ever had the pleasure of working with. They are respectful, understanding, efficient, and above all compassionate. They take the best care of their clients in every way possible. They keep us informed and aware of things involved in their clients cases. Their counsel is stellar in the industry. I would highly recommend them to others in their time of need and I have done so.

—Chad